PTPN3,也称为蛋白酪氨酸磷酸酶非受体型3,是一种膜相关非受体蛋白酪氨酸磷酸酶。PTPN3在细胞质中发挥重要作用,影响皮肤和毛发的发育和生长。PTPN3基因在多个生物学过程中发挥作用,包括免疫调节、细胞生长、信号传导和癌症发展。
PTPN3基因在免疫调节中发挥重要作用。PTPN3可以与T细胞受体(TCR)信号传导通路相互作用,影响T细胞的激活和增殖。研究发现,PTPN3的缺失可以导致T细胞功能异常,包括细胞因子产生和细胞增殖的异常[9]。此外,PTPN3还可以与乙型肝炎病毒(HBV)核心蛋白相互作用,抑制HBV基因的表达,从而发挥抗病毒作用[1]。
PTPN3基因在细胞生长和信号传导中也发挥重要作用。PTPN3可以抑制PI3K/AKT信号通路的激活,从而抑制细胞增殖和肿瘤的发生。研究发现,PTPN3的表达下调可以导致卵巢癌细胞对顺铂和脂质体阿霉素的耐药性增加,并促进细胞的干性特征[5]。此外,PTPN3的表达下调还可以导致肾透明细胞癌的细胞增殖和转移增加,并影响患者的预后[8]。
PTPN3基因的表达异常与多种癌症的发生和发展相关。研究发现,PTPN3的表达在多种癌症中上调,包括乳腺癌、肺腺癌和卵巢癌等[3][4]。PTPN3的表达上调与患者的预后不良相关,可以作为预测患者预后的生物标志物。此外,PTPN3的表达与肿瘤免疫微环境密切相关,可以影响免疫细胞浸润和免疫治疗的效果[4][6]。
PTPN3基因的表达受多种因素调控,包括基因突变、表观遗传修饰和信号通路。研究发现,PTPN3基因的突变可以导致其功能的改变,从而影响癌症的发生和发展[2][7]。此外,PTPN3基因的启动子甲基化状态也可以影响其表达,从而影响癌症的发生和发展[3]。信号通路,如PI3K/AKT信号通路,也可以影响PTPN3的表达,从而影响癌症的发生和发展[8]。
PTPN3基因在免疫调节、细胞生长、信号传导和癌症发展中发挥重要作用。PTPN3的表达异常与多种癌症的发生和发展相关,可以作为预测患者预后的生物标志物。PTPN3基因的表达受多种因素调控,包括基因突变、表观遗传修饰和信号通路。PTPN3的研究有助于深入理解其在免疫调节、细胞生长、信号传导和癌症发展中的作用,为癌症的诊断、治疗和预防提供新的思路和策略。
参考文献:
1. Hsu, En-Chi, Lin, Yen-Cheng, Hung, Chia-Shia, Yang, Shun-Chun, Ting, Ling-Pai. 2007. Suppression of hepatitis B viral gene expression by protein-tyrosine phosphatase PTPN3. In Journal of biomedical science, 14, 731-44. doi:. https://pubmed.ncbi.nlm.nih.gov/17588219/
2. Jung, Yeonjoo, Kim, Pora, Jung, Yeonhwa, Lee, Sanghyuk, Kim, Jaesang. 2012. Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing. In Genes, chromosomes & cancer, 51, 590-7. doi:10.1002/gcc.21945. https://pubmed.ncbi.nlm.nih.gov/22334442/
3. Abdel-Maksoud, Mostafa A, Ullah, Sajid, Nadeem, Amun, Al-Qahtani, Wahidah H, Hameed, Yasir. 2023. PTPN3 in cancer: unveiling its immune-mediated impact on prognosis and dysregulated signaling pathways. In American journal of translational research, 15, 6464-6475. doi:. https://pubmed.ncbi.nlm.nih.gov/38074816/
4. Zhou, Ziting, Lin, Zhengjun, Wang, Mingrui, Zhu, Guanghui, Liu, Tang. 2024. Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy. In European journal of medical research, 29, 12. doi:10.1186/s40001-023-01587-5. https://pubmed.ncbi.nlm.nih.gov/38173048/
5. Li, Shuqin, Cao, Jian, Zhang, Wei, Tao, Xiang, Xia, Hongping. 2016. Protein tyrosine phosphatase PTPN3 promotes drug resistance and stem cell-like characteristics in ovarian cancer. In Scientific reports, 6, 36873. doi:10.1038/srep36873. https://pubmed.ncbi.nlm.nih.gov/27833130/
6. Yan, Qianqian, Zhao, Zihao, Liu, Dongwei, Dong, Jiancheng, Liu, Zhangsuo. 2022. Integrated analysis of potential gene crosstalk between non-alcoholic fatty liver disease and diabetic nephropathy. In Frontiers in endocrinology, 13, 1032814. doi:10.3389/fendo.2022.1032814. https://pubmed.ncbi.nlm.nih.gov/36387855/
7. Wu, Chew-Wun, Chen, Jen-Hao, Kao, Hwa-Li, Chi, Chin-Wen, Lin, Wen-Chang. . PTPN3 and PTPN4 tyrosine phosphatase expression in human gastric adenocarcinoma. In Anticancer research, 26, 1643-9. doi:. https://pubmed.ncbi.nlm.nih.gov/16619586/
8. Peng, Xing-Si, Yang, Jun-Ping, Qiang, Yuan-Yuan, Huang, Bi-Jun, Qian, Chao-Nan. 2020. PTPN3 Inhibits the Growth and Metastasis of Clear Cell Renal Cell Carcinoma via Inhibition of PI3K/AKT Signaling. In Molecular cancer research : MCR, 18, 903-912. doi:10.1158/1541-7786.MCR-19-1142. https://pubmed.ncbi.nlm.nih.gov/32169891/
9. Bauler, Timothy J, Hughes, Elizabeth D, Arimura, Yutaka, Saunders, Thomas L, King, Philip D. . Normal TCR signal transduction in mice that lack catalytically active PTPN3 protein tyrosine phosphatase. In Journal of immunology (Baltimore, Md. : 1950), 178, 3680-7. doi:. https://pubmed.ncbi.nlm.nih.gov/17339465/